Research Projects & Grants

For Profit Organization

  • The quantitation of HCV RNA in whole blood samples obtained from individual subjects at specific time-points during the course of treatment of Hepatitis C, Role: Investigator, Discovery Life Sciences, Inc., (01/2021 - 01/2022) Status: Completed
  • NeuWave Medical Inc., NEU-2017-04: A multicenter observational registry to develop ablation parameter guidance for microwave liver ablation of soft tissue lesions, Role: Investigator, Neuwave Medical, Inc., (12/2019) Status: Approved
  • A randomized, global, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of once-daily oral avatrombopag for the treatment of adults with thrombocytopenia associated with liver disease prior to an elective procedure (Eisai, May 2015), Role: Investigator, Eisai Medical Research, Inc., (08/2016 - 08/2017) Status: Completed
  • A prospective, single-blind, randomized, phase III study to evaluate the safety and efficacy of fibrin sealant grifols (FS Grifols) as an adjunct to hemostasis during parenchymous tissue open surgeries (Protocol IG1102 version 2.1: 24 October 2012), Role: Investigator, Instituto Grifols, S.A., (03/2016 - 03/2017) Status: Completed
  • A multicenter, double-blind, placebo controlled study to evaluate the safety, tolerability and efficacy of IDN-6556 in subjects with liver cirrhosis (conatus cirrhosis 9Jun14), Role: Investigator, Conatus Pharmaceuticals Inc., (07/2015 - 07/2016) Status: Completed
  • A multicenter, randomized, open-label, active-controlled, trial to evaluate the safety and efficacy of rifaximin 550 mg with and without lactulose in subjects with a history of recurrent overt hepatic encephalopathy (RFHE, 4044-12Oct12), Role: Investigator, Salix Pharmaceuticals, Inc., (04/2014 - 04/2015) Status: Completed
  • Non-interventional, prospective, cohort study of the effectiveness, safety, and utilization of two approved pegylated interferon-based direct acting antiviral triple therapies in the management of Genotype 1 chronic Hepatitis C in routine clinical practice in the USA, Role: Investigator, Genentech, Inc., (03/2014 - 03/2015) Status: Completed
  • Global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib (GIDEON) NX0802, Role: Investigator, Bayer Healthcare, (05/2012 - 05/2013) Status: Completed
  • Prospective observational study on predictors of early on-treatment response and sustained virological response in a cohort of treatment naive HCV-infected patients treated with pegylated interferons, Role: Investigator, Hoffmann-La Roche Inc., (11/2010 - 11/2011) Status: Completed
  • Multicenter, randomized, open-labeled, controlled study of the effect of treatment with once weekly Pegasys® plus daily Copegus® with or without concomitant pioglitazone (Actos®) on early viral kinetics in treatment-naive patients with chronic hepatitis C (genotype-1 HCV infection) and insulin resistance, Role: Investigator, Hoffmann-La Roche Inc., (08/2010 - 08/2011) Status: Completed

Internal

  • Functional assessment in liver transplantation (FrAILT) study, Role: Investigator, LLU Dept. of Medicine, (03/2023 - 03/2024) Status: Completed
  • Pilot investigation using HCV positive liver grafts in HCV negative or previously successfully treated recipients, Role: Investigator, LLU Dept. of Medicine, (02/2022 - 02/2023) Status: Completed

Non-Profit Organization

  • Cirrhosis quality collaborative, Role: Investigator, American Association for the Study of Liver Diseases, (04/2019) Status: Completed
  • Introducing Palliative Care (PC) within the treatment of End Stage Liver Disease (ESLD): A cluster randomized controlled trial, Role: Investigator, Albert Einstein Healthcare Network, (12/2024 - 12/2025) Status: Approved